Bispecific Antibodies Demonstrate Potential in Providing Highly Effective Antiviral and Antifungal Therapies
Bispecific antibodies are artificial proteins that find application in the field of cancer immunotherapy. High prevalence of cancer has led to significant development in these antibodies. For instance, according to the World Health Organization’s Globocan 2018, Germany recorded 608,742 cases of cancer 247,462 cancer-related deaths in 2018. However, there are several issues in producing adequate quantities of bispecific antibodies. One of the biggest challenges in the development of these antibodies is producing adequate quantities by conventional biotechnological methods, including the chemical and hybridoma processes. Recently, there has been a major advancement in biotechnological approaches to improve the quality of bispecific antibodies, specifically artificial proteins, in the laboratory. Recent developments have resulted in the production of large numbers of artificial proteins that are more reliable and more potent than those developed in the past. The synthetic versions...